Butturini U, Coscelli C, Zavaroni I
Acta Diabetol Lat. 1977 Jan-Apr;14(1-2):73-8. doi: 10.1007/BF02624665.
The insulin response to oral glucose and to i.v tolbutamide was stuied in a group of hyperuricemic subjects and in a group of weight-matched controls. Glucose tolerance was impaired only in obese hyperuricemic subjects. Insulin response to oral glucose was enhanced in hyperuricemic subjects. Tolbutamide gave rise to a sharp increase in IRI levels already 2 min after the injection and this rise was significantly higher in hyperuricemic subjects than in controls. The same result was observed also after i.v. fructose. The interpretation of these data is not easy. Uric acid plasma level and obesity do not seem to be directly involved because an abnormal IRI response has been observed also after a rapid fall in uric acid plasma level after allopurinol treatment and is evident also in lean subjects. In our opinion the problem is more complex and must be considered from the point of view of a change involving carbohydrate as well as purine metabolism.
在一组高尿酸血症患者和一组体重匹配的对照组中,研究了口服葡萄糖和静脉注射甲苯磺丁脲后的胰岛素反应。只有肥胖的高尿酸血症患者存在糖耐量受损。高尿酸血症患者对口服葡萄糖的胰岛素反应增强。注射甲苯磺丁脲后仅2分钟,IRI水平就急剧上升,且高尿酸血症患者的这一上升幅度明显高于对照组。静脉注射果糖后也观察到了相同的结果。对这些数据的解释并不容易。血尿酸水平和肥胖似乎并非直接相关,因为在使用别嘌醇治疗后血尿酸水平迅速下降后,也观察到了异常的IRI反应,且在瘦人身上也很明显。我们认为这个问题更为复杂,必须从涉及碳水化合物以及嘌呤代谢变化的角度来考虑。